EASTONBIOPHARMACEUTICALS(SH:688513)2026-02-28 02:30Summary of the Conference Call Transcript Company Overview - The company discussed is Yuan Dong Bio (苑东生物), operating in the pharmaceutical industry, particularly focusing on controlled narcotics and innovative drug development. Key Financial Highlights - 2025 Financial Performance: - Total revenue: ¥1.331 billion (down 1.36%) - Net profit attributable to shareholders: ¥283 million (up 18.89%) - Non-recurring net profit: ¥206 million (up 18.01%) - Q4 revenue: ¥312 million (up 0.8%) - Q4 net profit: ¥63 million (up 197.2%) - Q4 non-recurring net profit: ¥33 million (up 376.9%) [1][2] - Adjusted Profit Forecast: - If stock incentive expenses are excluded, the net profit for 2025 is expected to exceed ¥300 million [2]. Revenue Drivers and Challenges - Revenue decline attributed to the 10th batch of national procurement, with three products (Naloxone, Shuqing, and Nortriptyline) expected to drop by over ¥150 million. - Despite this, products like Nabuphine, Butorphanol, and others are maintaining good growth, leading to overall revenue stability [2]. Profitability and R&D Focus - The company is actively integrating its R&D system and controlling costs for generic drugs and some innovative drugs. - Despite additional R&D expenses from the consolidation of Shanghai Chaoyang, the overall R&D expense ratio is expected to improve, a trend anticipated to continue into 2026 [2]. Future Growth Prospects - 2026 Revenue Expectations: - Revenue from controlled narcotics is projected to increase from ¥60 million in 2025 to over ¥200 million, driven by products like Nabuphine, Butorphanol, Ephedrine, and Oxazepam. - Approval of Acetaminophen-Oxycodone and Morphine-Naloxone is imminent, with participation in annual medical insurance negotiations expected [3]. - Profit Growth: - The company is expected to achieve a 20% profit growth in 2026 [3]. R&D Developments - Shanghai Chaoyang Platform: - HP-001 (IKZF1/3 molecular glue): Best-in-class single-agent data, currently in Phase IIa clinical trials with potential for conditional marketing approval. - HP-002 (BTK PROTAC): IND submission expected soon, with preclinical data outperforming competitors. - HP-003 (VAV1 molecular glue): Anticipated to be a new star in autoimmune potential, with Phase II POC data expected in mid-2026 and IND submission planned for H2 2026 [3][4]. - DAC Platform: - The company has established a complete targeted protein degradation platform, with competitive advantages in both TPD and DAC fields. The first DAC molecule, HP-004, shows significantly better data than combination therapies and is entering the Pre-IND stage [4].